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Background: The incidence and distribution of primary glomerulonephropathies vary throughout the world
and by race and ethnicity. We sought to evaluate the distribution of primary glomerulonephropathies among a
large racially and ethnically diverse population of the United States.
Study Design: Case series from January 1, 2000, through December 31, 2011.
Setting & Participants: Adults (aged $ 18 years) of an integrated health system who underwent native
kidney biopsy and had kidney biopsy findings demonstrating focal segmental glomerulosclerosis (FSGS),
membranous glomerulonephritis (MGN), minimal change disease (MCD), immunoglobulin A nephropathy
(IgAN), and other.
Outcomes: Rates and characteristics of the most common primary glomerulonephropathies overall and by
race and ethnicity.
Results: 2,501 patients with primary glomerulonephropathy were identified, with a mean age 50.6 years,
45.7% women, 36.1% Hispanics, 31.2% non-Hispanic whites, 17.4% blacks, and 12.4% Asians. FSGS was
the most common glomerulonephropathy (38.9%) across all race and ethnic groups, followed by MGN
(12.7%), MCD (11.0%), IgAN (10.2%), and other (27.3%). The FSGS category had the greatest proportion
of blacks, and patients with FSGS had the highest rate of poverty. IgAN was the second most common
glomerulonephropathy among Asians (28.6%), whereas it was 1.2% among blacks. Patients with MGN
presented with the highest proteinuria (protein excretion, 8.3 g) whereas patients with FSGS had the
highest creatinine levels (2.6 mg/dL). Overall glomerulonephropathy rates increased annually in our 12-year
observation period, driven by FSGS (2.7 cases/100,000) and IgAN (0.7 cases/100,000). MGN and MCD
rates remained flat.
Limitations:Missing data for urine albumin and sediment, indication bias in performing kidney biopsies, and
inexact classification of primary versus secondary disease.
Conclusions: Among a racially and ethnically diverse cohort from a single geographical area and similar
environment, FSGS was the most common glomerulonephropathy, but there was variability of other glo-
merulonephropathies based on race and ethnicity.
Am J Kidney Dis. 68(4):533-544. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
INDEX WORDS: Primary glomerulonephropathy; glomerulonephritis; nephrotic syndrome; focal segmental
glomerulosclerosis (FSGS); membranous glomerulonephritis (MGN); minimal change disease (MCD); IgA
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Sim et alThe distribution and incidence of the different pri-
mary glomerulonephropathies vary across countries,
race and ethnic groups, and time periods. This sug-
gests the possibility that multiple risk factors play a
role in glomerulonephropathy, including environment
and innate biological properties. Although immuno-
globulin A nephropathy (IgAN) has been the most
prevalent glomerulonephropathy described throughout
most countries,5-17 membranous glomerulonephritis
(MGN) or focal segmental glomerulosclerosis (FSGS)
is the most common in other countries, including the
United States.18-23 There have been variations in time
periods as well, with a trend toward increased rates
of FSGS in many countries.2,21,24 Certain race and
ethnic groups have been strongly linked with speciﬁc
glomerulonephropathies, such as IgAN among
Asians2,6,8,10,11 and FSGS among blacks.22 These
population-based studies have been drawn from pre-
dominantly homogeneous populations reﬂective of the
country or area of practice. Thus, aside from identiﬁed
genetic causes of certain glomerulonephropathies, the
contributions of environment and/or inborn physiog-
nomies on the risk for glomerulonephropathy is not
well known, but is the subject of much speculation.
Given the heterogeneous population of the United
States, it is not well known what the distributions of
glomerulonephropathies are within different race and
ethnic groups that reside in similar areas and envi-
ronments. Speciﬁcally, it would be of interest to
determine and compare the distribution of glomer-
ulonephropathies among Hispanics and Asians in
addition to whites and blacks within the United
States. We sought to characterize primary glomer-
ulonephropathies among a large ethnically diverse
contemporary adult population in the Southwestern4,440 Kaiser Permanente Southern California members with at least
renal biopsy between 01/01/2000 through 12/31/2011 were assesse
eligibility of inclusion into the study.
2,501 members included in analysis.
4,071 were 18 years or older at the time of biopsy.
369 were under the 
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534region of the United States. Using the health infor-
mation for more than 3 million members of an inte-
grated health system, we reviewed all native kidney
biopsies performed over a 12-year period. Based
on biopsy ﬁndings only, we identiﬁed diagnoses
presumed to be primary glomerulonephropathy to
determine the distribution of primary glomer-
ulonephropathies among the general population and
by different race and ethnic groups.
METHODS
Study Overview
A retrospective cohort study was performed in January 1, 2000,
through December 31, 2011, within the Kaiser Permanente
Southern California (KPSC) health system. KPSC is an integrated
prepaid health plan with 14 medical centers and more than 200
satellite medical ofﬁces that geographically spans from Bakersﬁeld
to San Diego, CA. As of July 2015, there were more than 4 million
KPSC members. The membership population is racially and
ethnically diverse, reﬂective of the underlying population and
Southern California in general.25-27 Compared to the distribution of
the US population, the KPSC membership has twice as many
Asians and 3 times as many Hispanics. Members have similar ac-
cess to health visits, medications, procedures, and medication and
supply beneﬁts. As part of routine clinical care, KPSC maintains all
member information collected in the electronic health record
(EHR). This includes information for demographics, comorbid
conditions, vital signs, laboratory and imaging results, pathology
reports, and medications. Race and ethnic information are entered
into the EHR based on either patient self-report or provider
assessment. Nearly all Hispanics within KPSC are Hispanic whites;
Hispanic blacks account for ,1% of KPSC members. Thus, the
designation of Hispanics within our study refers to Hispanic whites.
All laboratory measurements are performed and reported from an
American College of Pathology/Clinical Laboratory Improvement
Act (CLIA)-certiﬁed laboratory. Income information was derived
using resident address and the US Census tract information. This
study was approved by the local institutional review board (IRB
#5815) and exempted from informed consent. one 
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Figure 1. Study population flow diagram. In
January 1, 2000, through December 31, 2011, a to-
tal of 4,440 Kaiser Permanente Southern California
members had a kidney biopsy. Among this cohort,
369 were younger than 18 years and 308 had
inconclusive biopsy results. Another 138 had a
history of systemic lupus erythematous, and
1,124 were either transplant biopsies or findings
revealing secondary glomerulonephropathy (GN).
Thus, 2,501 individuals with primary glomerulone-
phropathy were included in the study cohort.
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Table 1. Study Population Characteristics by Most Common Primary Glomerulonephropathy Disease States, 2000-2011
FSGS
(n 5 973 [38.9%])
MGN
(n 5 317 [12.7%])
MCD
(n 5 274 [11.0%])
IgAN
(n 5 255 [10.2%])
Othera
(n 5 682 [27.3%])
Total
(N 5 2,501) P
Age at index date, y ,0.001
Mean 6 SD 51.16 16.21 52.0 6 15.35 49.9 6 17.45 42.8 6 13.23 52.5 6 17.93 50.6 6 16.67
Median 52 52 50 42 54 51
Range 18.0-91.0 18.0-83.0 18.0-87.0 18.0-84.0 18.0-91.0 18.0-91.0
Patient sex 0.004
Female 419 (43.1) 130 (41) 136 (49.6) 110 (43.1) 347 (50.9) 1142 (45.7)
Male 554 (56.9) 187 (59) 138 (50.4) 145 (56.9) 335 (49.1) 1359 (54.3)
Race/ethnicity ,0.001
Asian, non-Hispanic 129 (13.3) 28 (8.8) 26 (9.5) 73 (28.6) 55 (8.1) 311 (12.4)
Black, non-Hispanic 217 (22.3) 59 (18.6) 50 (18.2) 3 (1.2) 107 (15.7) 436 (17.4)
Hispanic 325 (33.4) 113 (35.6) 89 (32.5) 105 (41.2) 271 (39.7) 903 (36.1)
Other, non-Hispanic 22 (2.3) 4 (1.3) 16 (5.8) 9 (3.5) 19 (2.8) 70 (2.8)
White, non-Hispanic 280 (28.8) 113 (35.6) 93 (33.9) 65 (25.5) 230 (33.7) 781 (31.2)
Neighborhood household
incomeb
0.03
Mean 6 SD, in
1,000’s USD
61.1 6 26.8 62.7 6 27.0 65.1 6 28.0 65.86 25.6 64.0 6 28.2 63.0 6 27.3
,$25,000 66 (6.8) 13 (4.1) 17 (6.2) 11 (4.3) 30 (4.4) 137 (5.5)
$25,000-$49,999 341 (35) 111 (35) 70 (25.5) 72 (28.2) 223 (32.7) 817 (32.7)
$50,000-$99,999 487 (50.1) 157 (49.5) 160 (58.4) 147 (57.6) 365 (53.5) 1,316 (52.6)
$$100,000 79 (8.1) 36 (11.4) 27 (9.9) 25 (9.8) 64 (9.4) 231 (9.2)
History of hypertension 734 (75.4) 195 (61.5) 153 (55.8) 156 (61.2) 431 (63.2) 1,669 (66.7) ,0.001
History of diabetes 274 (28.2) 51 (16.1) 38 (13.9) 30 (11.8) 141 (20.7) 534 (21.4) ,0.001
Body mass index ,0.001
No. with data 681 203 112 219 379 1,594
Mean 6 SD, kg/m2 30.9 6 7.34 30.2 6 6.16 31.9 6 7.93 29.06 6.21 28.7 6 6.47 30.1 6 6.97
#25 kg/m2 150 (22) 38 (18.7) 20 (17.9) 57 (26) 117 (30.9) 382 (24)
25-,30 kg/m2 200 (29.4) 76 (37.4) 32 (28.6) 84 (38.4) 120 (31.7) 512 (32.1)
30-#35 kg/m2 158 (23.2) 49 (24.1) 27 (24.1) 48 (21.9) 88 (23.2) 370 (23.2)
.35 kg/m2 173 (25.4) 40 (19.7) 33 (29.5) 30 (13.7) 54 (14.2) 330 (20.7)
Note: Unless otherwise indicated, values are given as number (percentage). Percentages are totaled across the individual columns.
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, immunoglobulin A nephropathy; MCD, minimal change disease;
MGN, membranous glomerulonephritis; SD, standard deviation; USD, US dollar.
aIncluded immune complex glomerulonephropathy not otherwise specified (n 5 206), pauci immune/antineutrophil cytoplasmic
antibody–associated glomerulonephropathy (n5 178), thin basement membrane disease (n 5 121), membranoproliferative glomer-
ulonephritis (n5 50), crescentic glomerulonephropathy not otherwise specified (n 5 48), postinfectious glomerulonephritis, anti–
glomerular basement membrane disease, fibrillary glomerulonephropathy, dense deposit disease, and others.
bNeighborhood income is not reported income but is estimated on the basis of members’ addresses using neighborhood income
from US Census tract information.
Primary Glomerulonephropathy Distribution in United StatesStudy Population
All members 18 years and older who underwent a native kidney
biopsy were identiﬁed for potential inclusion in the study cohort. In-
dividual paper and electronic chart reviewswereperformed to identify
and categorize biopsy ﬁndings and diagnoses. Biopsies that had a
main diagnosis of primary glomerulonephropathy were included in
the study. For individuals who had multiple biopsies, the ﬁrst biopsy
result was used in our study and analyses. Primary glomerulone-
phropathies to be identiﬁed on chart review included FSGS, IgAN,
minimal change disease (MCD), MGN, membranoproliferative
glomerulonephritis (MPGN) including dense deposit disease, pauci-
immune glomerulonephritis/antineutrophil cytoplasmic antibody
(ANCA)-associated glomerulonephritis, immune complex nephro-
pathy, crescentic glomerulonephritis not otherwise speciﬁed, post-
infectious glomerulonephritis, anti–glomerular basement membrane
glomerulonephritis, ﬁbrillary glomerulonephritis, and others. Exclu-
sion criteria were members younger than 18 years at the time of
biopsy, transplant biopsies, history of systemic lupus erythematousAm J Kidney Dis. 2016;68(4):533-544(SLE), and biopsies that demonstrated inconclusive ﬁndings or
a secondary glomerulonephropathy. Secondary glomeruloneph-
ropathies that were excluded were diabetic glomerulosclerosis, SLE-
associated nephritis, amyloidosis, nephrocalcinosis, Bence-Jones/cast
nephropathy, myelodysplastic disorder–associated glomerulone-
phropathy, human immunodeﬁciency virus (HIV)-associated ne-
phropathy, urate nephropathy, sarcoidosis, Alport disease, light or
heavy chain deposition disease, and oxalate nephropathy.
Kidney Biopsies at KPSC
All kidney biopsy information in the study period was obtained
from routine clinical practice, whereby all biopsies were deter-
mined as clinically indicated by the practitioners. Kidney biopsies
are performed in both the inpatient and outpatient settings, with
nearly all member biopsies occurring at a KPSC medical center.28
Approximately 3% are performed at non-KPSC facilities, but all
specimens are transported to the KPSC renal pathology depart-
ment for processing and reading. All samples are received at the535
Table 2. Clinical Laboratory Markers by Most Common Biopsy-Proven Primary Glomerulonephropathy Disease States, 2000-2011
FSGS (n 5 973 [38.9%]) MGN (n 5 317 [12.7%]) MCD (n 5 274 [11.0%]) IgAN (n 5 255 [10.2%]) Other (n 5 682 [27.3%]) Total (N 5 2,501) P
Serum creatinine ,0.001
No. with data 954 310 262 253 654 2,433
Mean 6 SD, mg/dL 2.66 1.9 1.4 6 1.0 1.76 1.4 1.96 1.5 3.1 6 2.5 2.4 6 2.0
Median [IQR], mg/dL 2.1 [1.4-3.2] 1.1 [0.8-1.5] 1.3 [0.8-2.1] 1.5 [1.1-2.1] 2.2 [1.3-3.9] 1.7 [1.1-2.9]
Range, mg/dL 0.4-15.4 0.4-8.3 0.4-10.6 0.5-15.0 0.5-15.2 0.4-15.4
eGFRa ,0.001
No. with data 954 310 262 253 654 2,433
Mean 6 SD, mL/min/1.73 m2 40.6 6 28.2 74.5 6 34.3 64.3 6 37.9 56.2 6 31.3 40.6 6 34.1 49.1 6 34.5
Median [IQR], mL/min/1.73 m2 32.5 [19.8-54.4] 76.1 [47.8-101.4] 60.7 [31.3-94.8] 49.4 [33.1-79.5] 30.3 [13.2-57.4] 39.9 [21.3-71.4]
Range, mL/min/1.73 m2 3.8-143.5 6.1-153.8 4.3-157.1 3.4-137.4 3.0-136.8 3.0-157.1
SUN, mg/dL ,0.001
No. with data 943 310 261 249 649 2412
Mean 6 SD 35.1 6 21.6 20.9 6 14.9 27.9 6 22.0 27.1 6 17.7 40.0 6 25.5 33.0 6 22.6
Median [IQR] 30 [19.0-44.0] 17 [12.0-24.0] 21 [13.0-35.0] 21 [16.0-34.0] 33 [20.0-55.0] 26 [17.0-43.0]
Range 6.0-130.0 6.0-115.0 6.0-133.0 7.0-101.0 6.0-138.0 6.0-138.0
Serum albumin ,0.001
No. with data 854 299 242 217 595 2,207
Mean 6 SD, g/dL 3.36 0.8 2.4 6 0.8 2.86 1.1 3.66 0.6 3.0 6 0.8 3.1 6 0.9
Median [IQR], g/dL 3.5 [2.9-3.9] 2.3 [1.8-3.1] 3 [1.8-3.7] 3.7 [3.3-4.0] 3.1 [2.4-3.6] 3.3 [2.4-3.8]
Range, g/dL 1.0-4.8 0.9-4.6 0.9-4.7 1.4-4.7 0.9-4.8 0.9-4.8
Urine protein quantification 710 (73.0) 220 (69.4) 148 (54.0) 214 (83.9) 393 (57.6) 1,685 (67.4) ,0.001
24-h urinary total protein ,0.001
No. with data 227 103 34 92 82 538
Mean 6 SD, g 4.96 5.2 8.3 6 6.4 6.76 4.8 2.36 1.9 3.4 6 3.3 5.0 6 5.2
Median [IQR], g 3.3 [1.5-6.2] 6.5 [3.5-11.0] 4.8 [3.5-8.9] 1.6 [0.8-3.5] 2.1 [0.7-5.1] 3.4 [1.5-6.5]
Range, g 0.1-30.9 0.7-31.8 0.2-17.1 0.0-7.7 0.1-13.2 0.0-31.8
Urine PCR ,0.001
No. with data 452 131 68 145 218 1,014
Mean 6 SD, g/g 4.66 4.4 8.3 6 5.4 5.36 4.6 2.36 2.1 3.5 6 4.4 4.6 6 4.6
Median [IQR], g/g 3.4 [1.5-6.5] 7.2 [4.3-11.6] 3.8 [1.6-8.4] 1.7 [0.8-3.2] 1.9 [0.9, -4.2] 3 [1.3-6.3]
Range, g/g 0.1-24.9 0.4-28.7 0.1-19.3 0.1-15.4 0.1-24.1 0.1-28.7
(Continued)
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Primary Glomerulonephropathy Distribution in United StatesKPSC regional laboratory in North Hollywood, CA, for processing
and preparation. All samples are separately prepared in
hematoxylin-eosin, Masson trichrome, periodic acid–Schiff, and
Jones methenamine silver stains for light microscopy viewing.
Immunoﬂuorescence studies and electron microscopy viewing are
performed on all specimens. When prepared, samples are sent to
Los Angeles Medical Center for review and interpretation by 2
renal pathologists. After each renal pathologist views the speci-
mens separately, the ﬁnal diagnoses are determined after a
consensus is reached by the 2 renal pathologists.
Kidney biopsy results were extracted by chart review performed
by 4 research associates (see Acknowledgements). Results were
categorized based on the primary diagnoses as reported on the
pathology report. Any discrepancies in results were adjudicated by
both a nephrologist (J.J.S.) and a renal pathologist (A.H.). If there
were 2 primary diagnoses, a prioritization algorithm was used to
consistently and reliably prioritize based on which primary
glomerulonephropathy would be more likely (Fig S1, available as
online supplementary material). For example, FSGS is often a
descriptive ﬁnding and also a primary glomerulonephropathy.
When another concrete glomerulonephropathy such as IgAN or
MPGN was reported concurrently as the primary diagnosis, those
primary glomerulonephropathies would take precedence over
FSGS as the primary biopsy diagnosis.
Analysis Plan
The objective of the study was to identify all KPSC members
who had biopsy-proven primary glomerulonephropathy and
determine the distribution and characteristics of the common
glomerulonephropathies among race and ethnic groups. Demo-
graphic and laboratory characteristics were compared across the 4
most prevalent glomerulonephropathies using c2 or Fisher exact
test for categorical variables and Kruskal-Wallis or analysis of
variance for continuous variables, as appropriate. Shapiro-Wilks
test of normality assessed the normality assumption of para-
metric tests. In addition, we reported age- and sex-adjusted
(standardized) rates among patients overall and for the 4 most
prevalent glomerulonephropathies (FSGS, MCD, IgAN, and
MGN) by year to determine average annual rates of the different
glomerulonephropathies in our observation window. Using
KPSC’s electronic enrollment records for each patient, we ﬁrst
combined all enrollment periods with less than a 30-day gap in
enrollment coverage. The person-time denominator for each rate is
the number of patients who were members at any stage in the year
by age, sex, and year weighed by the time each person was a
member in that year. For example, a man in 2002 who was a
member for 6 calendar months would contribute 0.5 male-year to
the 2002 denominator. The numerator is the sum of the number of
patients who had each reported event in that year. Age- and sex-
adjusted rates were subsequently directly standardized to the 2000
age and sex distribution of the United States.29 Use of the US
Standard Population in 2000 for age and sex adjustment ensures
valid comparison of the rates computed for each of the study
years. Standard errors for the rates are estimated assuming a
Poisson distribution. All rates are reported per 100,000 person-
years, all tests were 2 sided, and all analyses were performed
using SAS, version 9.3 (SAS Institute Inc).
RESULTS
Biopsy Numbers and Study Population
A total of 4,440 kidney biopsies were performed at
KPSC in January 1, 2000, through December 31,
2011. There were 369 biopsies performed on mem-
bers younger than 18 years, 1,124 biopsies were either
transplant biopsies or had a diagnosis of secondary537
Table 3. Age- and Sex-Adjusted Incidence of the Most Common Biopsy-Proven Primary Glomerulonephropathy Disease States by Year and All Years Combined
Among Members, 2000-2011
2000
(n 5 145)
2001
(n 5 144)
2002
(n 5 139)
2003
(n 5 169)
2004
(n 5 174)
2005
(n 5 172)
2006
(n 5 216)
2007
(n 5 206)
2008
(n 5 222)
2009
(n 5 258)
2010
(n 5 303)
2011
(n 5 353)
All Years
Combined
Overall
New cases 145 144 139 169 174 172 216 206 222 258 303 353 2,501
Person-y
at risk
2,084,875 2,151,545 2,231,244 2,226,002 2,190,386 2,236,411 2,313,282 2,368,610 2,391,020 2,402,749 2,439,293 2,567,451 27,602,867
Rate 5.3 5.3 4.7 5.7 6.3 5.8 7.4 7.3 7.3 8.9 9.7 10.7 7.1
SE 0.5 0.5 0.4 0.5 0.6 0.5 0.6 0.6 0.6 0.7 0.7 0.6 0.2
FSGS
New cases 49 55 42 54 40 64 71 82 84 113 133 186 973
Person-y
at risk
2,084,875 2,151,545 2,231,244 2,226,002 2,190,386 2,236,411 2,313,282 2,368,610 2,391,020 2,402,749 2,439,293 2,567,451 27,602,867
Rate 1.6 2 1.3 1.7 1.4 2.1 2.5 2.9 3 3.8 4.1 5.3 2.7
SE 0.2 0.3 0.2 0.2 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.1
MGN
New cases 16 14 15 24 31 20 29 34 34 23 33 44 317
Person-y
at risk
2,084,875 2,151,545 2,231,244 2,226,002 2,190,386 2,236,411 2,313,282 2,368,610 2,391,020 2,402,749 2,439,293 2,567,451 27,602,867
Rate 0.7 0.6 0.5 0.8 1 0.6 0.9 1 1 0.7 1 1.4 0.9
SE 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1
MCD
New cases 34 29 32 21 28 24 34 14 15 17 11 15 274
Person-y
at risk
2,084,875 2,151,545 2,231,244 2,226,002 2,190,386 2,236,411 2,313,282 2,368,610 2,391,020 2,402,749 2,439,293 2,567,451 27,602,867
Rate 1.2 1.2 1.2 0.7 0.9 0.8 1.1 0.8 0.4 0.6 0.5 0.4 0.8
SE 0.2 0.3 0.3 0.1 0.2 0.2 0.2 0.3 0.1 0.2 0.2 0.1 0.1
IgAN
New cases 4 9 6 7 7 6 13 37 37 34 52 43 255
Person-y
at risk
2,084,875 2,151,545 2,231,244 2,226,002 2,190,386 2,236,411 2,313,282 2,368,610 2,391,020 2,402,749 2,439,293 2,567,451 27,602,867
Rate 0.1 0.3 0.2 0.2 0.2 0.2 0.4 1.4 1.1 1.2 1.6 1.6 0.7
SE 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.3 0.1
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Primary Glomerulonephropathy Distribution in United Statesglomerulonephropathy, and 308 kidney biopsies had
an inconclusive result; 138 members were excluded
for having a history of SLE. Thus, a total of 2,501
native kidney biopsies that had a diagnosis of
primary glomerulonephropathy were included in our
study (Fig 1). Mean age of the study population was
50.6 6 16.7 (standard deviation) years, with 45.7%
being women. Hispanics accounted for 36.1% of the
study population, followed by non-Hispanic whites
(31.2%), blacks (17.4%), Asians (12.4%), and others
(2.8%; Table 1). In terms of comorbid conditions,
hypertension (66.7%) and diabetes mellitus (21.4%)
were prevalent among the study population. Ninety-
ﬁve percent of the cohort had household income in
the $25,000 to $99,999 range.
Distribution and Characteristics of
Glomerulonephropathies
Among the 4 most prevalent primary glomer-
ulonephropathies, FSGS was most common (n5 973
[38.9%]), followed by MGN (n 5 317 [12.7%]),
MCD (n5 274 [11.0%]), and IgAN (n5 255
[10.2%]; Table 1). A total of 682 (27.3%) biopsies
were categorized as other, which included immune
complex glomerulonephropathy not otherwise speci-
ﬁed, pauci-immune/ANCA-associated glomerulone-
phropathy, thin basement membrane disease,
membranoproliferative glomerulonephropathy, cres-
centic glomerulonephropathy not otherwise speciﬁed,
postinfectious glomerulonephritis, anti–glomerular
basement membrane disease, ﬁbrillary glomerulone-
phropathy, dense deposit disease, and others. Of
those, the descriptive category of immune complex
nephropathy not otherwise speciﬁed (n 5 206) and
pauci-immune/ANCA-associated glomerulonephritis
(n 5 178) accounted for the largest proportion. There
were 50 diagnoses of MPGN, which accounted for
2.0% of study population (Table S1).
Laboratory ﬁndings with mean and median values
are reported in Table 2. Mean and median serum
creatinine values at the time of kidney biopsy were
2.4 mg/dL (estimated glomerular ﬁltration rate,
49 mL/min/1.73 m2) and 1.7 mg/dL (estimated
glomerular ﬁltration rate, 40 mL/min/1.73 m2),
respectively (Table 2). The highest creatinine level at
biopsy was in the “other” glomerulonephropathy
group (3.1 mg/dL), followed by FSGS (2.6 mg/dL)
and IgAN (1.9 mg/dL). Mean serum albumin level
was 3.1 g/dL for the cohort; MGN had the lowest
mean serum albumin level (2.4 g/dL). Urine protein
quantiﬁcation as reported by spot ratios was available
in up to 67.4% of the study cohort. Mean urine
protein-creatinine ratio was 4.6 g/g, and mean urine
albumin-creatinine ratio was 2.8 g/g. Whereas
MGN had the highest levels of proteinuria (protein-
creatinine ratio, 8.3 g/g; albumin-creatinine ratio,539
Sim et al5.2 g/g), IgAN had the lowest degree of proteinuria
(protein-creatinine ratio, 2.3 g/g; albumin-creatinine
ratio, 1.5 g/g). Hematuria was present among 65%
of patients with IgAN and 71% of biopsies catego-
rized as other (Table 2).
Distribution of Glomerulonephropathies by Race and
Ethnicity
Among all race and ethnic groups, FSGS was the
most common glomerulonephropathy (Table 1). In
the black population, FSGS accounted for 49.8%,
followed by MGN (13.5%) and MCD (11.5%). There
were only 3 cases of IgAN diagnosed among blacks
within our study period. The distribution of glomer-
ulonephropathies in non-Hispanic whites was similar
to blacks, with FSGS (35.9%) being most prevalent,
followed by MGN (14.5%), MCD (11.9%), and IgAN
(7.8%). Among Asians, FSGS was most prevalent
(41.5%), followed by IgAN (23.5%), MGN (9.0%),
and MCD (8.4%). Among Hispanics, FSGS accoun-
ted for 36.0%, followed by MGN (12.5%), IgAN
(11.6%), and MCD (9.9%).
Rates of Primary Glomerulonephropathies During the
Observation Period
Age- and sex-adjusted rates of primary glomer-
ulonephropathies by year are shown in Table 3 and
Fig 2. In the 12-year observation period, annual rates0
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Figure 2. The distribution of primary glomerulonephropathy in the
sis (FSGS) rates, and to a lesser degree immunoglobulin A (IgA) nep
disease and membranous glomerulonephritis rates remained flat thro
mune complex glomerulonephritis not otherwise specified, pauci-imm
nephritis, thin basement membrane disease, membranoproliferative
specified, postinfectious glomerulonephritis, anti–glomerular baseme
disease, and others.
540of glomerulonephropathies had steadily increased
from 5.3 cases in 2000 to 10.7 cases (per 100,000
person-years) in 2011. Among the common glomer-
ulonephropathies, rates were highest for FSGS (2.7
cases/100,000 person-years), followed by MGN,
IgAN, and MCD (Table 4). FSGS also had the
greatest increase in rate from 1.6 cases in 2000 to
5.3 cases (per 100,000 person-years) in 2011. This
increase was observed in all race and ethnic groups
(Table 4; Fig 3). IgAN increased in rate from 0.1 to
1.6 cases (per 100,000 person-years). The increased
rate of IgAN was driven by Hispanics and non-
Hispanic Asians. The overall rate of MGN appeared
to remain stable, although it increased among blacks.
The rate of MCD declined to 0.4 case (per 100,000
person-years) by 2011 (Table 3).
Sensitivity Analyses
In order to exclude potential bias against perform-
ing kidney biopsies in certain populations, we per-
formed sensitivity analyses evaluating rates of
primary glomerulonephropathies among individuals
who were younger than 80 years and who did not
have diabetes mellitus. Within this subpopulation
(n 5 1,838), FSGS was also the most common pri-
mary glomerulonephropathy (n 5 651), followed by
MGN (n 5 252), MCD (n 5 224), and IgAN
(n 5 218; Tables S2 and S3).2006 
(n=216)
2007 
(n=206)
2008 
(n=222)
2009 
(n=258)
2010 
(n=303)
2011 
(n=353)
AR
nimal Change IgA Other
12-year observation window. Focal segmental glomerulosclero-
hropathy rates, increased throughout the period. Minimal change
ughout our observation period. The “other” category included im-
une/antineutrophil cytoplasmic antibody–associated glomerulo-
glomerulonephritis, crescentic glomerulonephritis not otherwise
nt membrane disease, fibrillary glomerulonephritis, dense deposit
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Table 4. Members’ Age- and Sex-Adjusted Rates of Glomerulonephropathy Types by Race and Ethnicity and Combined, 2000-2011
White,
Non-Hispanic
Black,
Non-Hispanic Hispanic
Asian,
Non-Hispanic
Other,
Non-Hispanic
All Groups
Combined
Overall
New cases 781 436 903 311 70 2,501
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 5.9 13.62 9.74 10.61 1.37 7.15
SE 0.29 0.77 0.38 0.7 0.2 0.16
FSGS
New cases 280 217 325 129 22 973
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 1.89 6.81 3.72 4.26 0.41 2.73
SE 0.13 0.55 0.25 0.4 0.1 0.1
MGN
New cases 113 59 113 28 4 317
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 0.78 1.62 1.09 0.82 0.06 0.85
SE 0.09 0.22 0.12 0.16 0.03 0.05
MCD
New cases 93 50 89 26 16 274
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 0.67 1.61 0.96 0.93 0.31 0.8
SE 0.1 0.28 0.12 0.19 0.09 0.06
IgAN
New cases 65 3 105 73 9 255
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 0.72 0.1 0.96 2.75 0.13 0.75
SE 0.12 0.06 0.1 0.44 0.04 0.05
Other
New cases 230 107 271 55 19 682
Person-y at risk 9,857,160 2,546,554 8,051,203 2,237,143 4,910,807 27,602,867
Rate 1.84 3.48 3.01 1.85 0.46 2.02
SE 0.18 0.41 0.22 0.27 0.13 0.09
Note: Age- and sex-adjusted rates of primary glomerulonephropathy by race and ethnic groups. Rates paralleled the overall dis-
tribution of primary glomerulonephropathy. All rates are reported as per 100,000 person-years and standardized to the US Census
2000 population. Population at risk is the overall Kaiser Permanente Southern California population, 18 years or older, in that race and
ethnic category in the study period.
Abbreviations: FSGS, focal segmental glomerulosclerosis; IgAN, immunoglobulin A nephropathy; MCD, minimal change disease;
MGN, membranous glomerulonephritis; SE, standard error.
Primary Glomerulonephropathy Distribution in United StatesDISCUSSION
Historically, the distribution and prevalence of
glomerulonephropathies has been described by pool-
ing separate studies of relatively homogeneous pop-
ulations in speciﬁc countries or areas throughout the
world. In our study, we had an opportunity to describe
the distribution of glomerulonephropathies within a
single yet heterogeneous population living in a similar
environment of Southern California, but differing in
race and ethnic roots. A total of 2,501 individuals
with biopsy-proven primary glomerulonephropathy
were identiﬁed from a large racially and ethnically
diverse contemporary population in Southern Cali-
fornia. We found that FSGS was the most prevalent
primary glomerulonephropathy, with racial and ethnic
variations occurring in the distribution of the different
glomerulonephropathies. FSGS accounted for 38.9%Am J Kidney Dis. 2016;68(4):533-544of the biopsy ﬁndings, followed by MGN, MCD,
and IgAN. Patients with MGN presented with the
greatest degree of proteinuria, whereas those with
FSGS presented with the lowest kidney function
among the 4 common glomerulonephropathies.
Overall, glomerulonephropathy rates increased in our
12-year observation period, driven by increasing rates
of FSGS and IgAN.
Glomerulonephropathy is an important cause of
chronic kidney disease in the United States and
worldwide. Overall, glomerulonephropathies are
generally considered treatable, and if diagnosed and
managed early, kidney damage and progression to
failure can be potentially avoided. Nevertheless, tens
of thousands of patients initiate dialysis therapy or
receive kidney transplants annually in the United
States as a consequence of glomerulonephropathies.3541
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Figure 3. Average annual age- and sex-adjusted rates for the most common primary glomerulonephropathy disease states by race
and ethnicity, 2000 to 2011. Rates for the primary glomerulonephropathy and by different race and ethnic groups were similar to the
distribution for the entire period. Abbreviations: FSGS, focal segmental glomerulosclerosis; IgA, immunoglobulin A.
Sim et alPatient predilections for glomerulonephropathy are
variable, affecting all age groups and sexes and those
with comorbid conditions.
We think that our ﬁndings lend insight into the
nature-versus-nurture aspects of glomerulonephropa-
thy. Aside from the familial/genetic glomeruloneph-
ropathies, the contributions of innate biology and
environmental exposure on glomerulonephropathy risk
are difﬁcult to quantitate or study. Certain glomer-
ulonephropathies occur more frequently in different
parts of the world and certain glomerulonephropathies
are more common in speciﬁc populations or race and
ethnic groups.2,30 Woo et al2 have suggested that in-
fections, sanitation/hygiene, and overstimulated im-
mune function may be the underlying mechanisms for
these differences. Whereas FSGS may be a byproduct
or consequence of the increasing trend of worldwide
obesity, within the United States, there have been
varying observations suggesting a race predilection
(FSGS in blacks and MGN in whites) and perhaps by
time periods (in the past, there has been more MGN
described, whereas more recently, FSGS is more
frequently described).21,22,24,31
Our study cohort included a racially and ethnically
diverse population all living in a Westernized
environment of Southern California. We originally
hypothesized that blacks would have more FSGS542and Asians would have more IgAN. We observed
that FSGS was the most predominant primary
glomerulonephropathy among all race groups
including Asians. Individuals with FSGS had the
highest rate of poverty (6.8%) and appeared to present
in more advanced stages of chronic kidney disease,
which may suggest a socioeconomic predilection and
an association with access to care. The high rate of
FSGS is consistent with previous observations within
the United States that evaluated less diverse pop-
ulations in the Midwestern and Eastern United States,
where FSGS accounted for 12% to 25% of bi-
opsies.20,21 However, other observations within the
United States have reported IgAN as the most common
ﬁnding, seen in up to 22% of all biopsies.31,32 Annual
rates of glomerulonephropathies increased in our
observation period, which was driven by higher rates
of FSGS and to a lesser degree by IgAN. MGN and
MCD rates remained ﬂat, which was also consistent
with trends observed in previous US studies.21,24 We
think that the high FSGS rates in our study reﬂect the
Westernization of the different race and ethnic groups
in terms of lifestyles and environmental exposures,
including diet. However, we did not have information
about body mass index available for the entire study
cohort, which would provide additional insights
into obesity trends paralleling FSGS theories.Am J Kidney Dis. 2016;68(4):533-544
Primary Glomerulonephropathy Distribution in United StatesThere are several potential limitations that may
confound the interpretation of our study ﬁndings. Our
study population was drawn from insured members of
an integrated health system and thus may not neces-
sarily reﬂect the US general population. Our study
cohort had similar socioeconomic status relative to the
underlying KPSC membership population from which
they were drawn25 and thus may not be representative
of those in the extremes of wealth, including those with
no insurance and those who preferred to self-pay for
health care. The kidney biopsy population also may
have been a reﬂection of those seeking health care more
frequently and those willing to undergo invasive diag-
nostic testing. Individuals with more indolent glomer-
ulonephropathies such as IgAN may have been
underdiagnosed compared with other studies in which
there was active screening for kidney disease.33 We did
not have reasons or indications for biopsy for the entire
study population. In addition, a signiﬁcant proportion
of our biopsy ﬁndings were categorized descriptively as
immune-complex nephropathy, which likely included
early or inconclusive IgAN or MPGN that were not
diagnosed. Each glomerulonephropathy was given one
primary diagnosis using a hierarchical schema and thus
we may have under-reported when patients had 2
legitimate primary glomerulonephropathy diagnoses.
In a similar regard, primary glomerulonephropathy
was determined somewhat arbitrarily because
certain glomerulonephropathies (eg, ANCA-associated
glomerulonephropathy) can be categorized as a sec-
ondary glomerulonephropathy similar to SLE. We
excluded patients who had a diagnosis of SLE in
order to rule out systemic diseases that resulted
in glomerulonephropathy and attempted to include
conditions that solely had renal involvement as primary
glomerulonephropathy. Thus our primary glomer-
ulonephropathies are “presumed” given the lack of
complete history for each biopsy patient. We also could
not account for recent immigrants who may have
constituted the different race and ethnic groups andmay
be less representative of the Southern California
population.
Despite these potential limitations, our study is one of
the largest racially and ethnically diverse kidney biopsy
cohorts described to date. Our EHR-based study
included comprehensive information for patient de-
mographics, including socioeconomics, comorbid
conditions, laboratory information, and medications.
We believe that the comprehensive and longitudinal
information for medication use and overall utilization
through the EHR within our integrated health system
may pave the way to providing valuable insights
into the natural history of glomerulonephropathies and
also assess comparative management strategies. When
we can assess comparative management strategies,
it may be possible to use the database generated inAm J Kidney Dis. 2016;68(4):533-544this study as a prospective glomerulonephropathy reg-
istry that can track patients over time, drive de-
cision support and case management, and serve as a tool
to ensure that all patients are followed up appropriately,
as we have done for many other chronic diseases.34
Our kidney biopsy cohort drawn from a large racially
and ethnically diverse population of the United States
demonstrated an increase in rates of primary glomer-
ulonephropathies within the 12-year observation
period. The most prevalent glomerulonephropathy
among all race and ethnic groups, including Asians and
Hispanics, was FSGS. Our study cohort derived using
an EHR-based approach with comprehensive longitu-
dinal information has the potential to provide valuable
insights into characterizing primary glomeruloneph-
ropathies and studying their outcomes.
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